Market Size of North America Clinical Trials Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 8.10 % |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
North America Clinical Trials Market Analysis
The North America clinical trials market is expected to register a CAGR of 8.1% during the forecast period.
The emergence of the COVID-19 pandemic had an adverse effect on the world economy and the healthcare system. The lockdown all over the globe has affected the supply chain of pharmaceuticals, medical devices, and biotechnological products. On the other hand, research and development have come into focus. All government agencies and healthcare players all over the world have increased their focus to support the development of prevention, diagnostics, and treatment methods for COVID-19. This led to an increase in the number of clinical trials focusing on COVID-19 medication, which majorly benefitted the market growth.
The market will show rapid growth due to the increasing number of clinical trials in the North American region, the high R&D expenditure of the pharmaceutical industry, and the rising prevalence of diseases.
The rising population in the North American region is found to have has varied disease profiles which are increasing with the span of time and this is expected to boost the clinical trials of new or rare diseases. Therefore the number of patients having a specific disease would act as a stimulus for biopharmaceutical companies to invest more in clinical trials for a disease segment.
According to the United States National Library of Medicine, as of September 2022, there are approximately 13,323 active clinical trials across different phases for cancer indication in the United States. The research and development (R&D) spending of pharmaceutical companies has also been steadily increasing over the past few years. This was mainly due to numerous patent expiries, and as a result of the patent expiration, many pharmaceutical companies will have no other option but to develop new drugs. Therefore, the companies are spending more on R&D to accelerate the development of drugs through clinical trials, henceforth increasing the overall market.
North America Clinical Trials Industry Segmentation
As per the scope of the report, clinical trials are experiments that are conducted under clinical research and follow a regulated protocol. These experiments are primarily performed to obtain data regarding the safety and efficacy of newly developed drugs. Clinical trial data is mandatory for drug approval, as well as for it to be introduced in the market. These trials are performed under three phases (I, II, III, and IV), which depend upon various factors. This process is not only expensive, but also time-consuming, and requires expertise at all stages. The North America Clinical Trials Market is segmented By Phase (Phase I, Phase II, Phase III, and Phase IV), By Design (Treatment Studies and Observational Studies), and Geography (United States, Canada, and Mexico). The report offers the value in USD (US Dollar) million for the above segments.
| By Phase | |
| Phase I | |
| Phase II | |
| Phase III | |
| Phase IV |
| By Design | |||||||||
| |||||||||
|
| Geography | |
| United States | |
| Canada | |
| Mexico |
North America Clinical Trials Market Size Summary
The North America clinical trials market is poised for significant growth, driven by an increasing number of trials and substantial investments in research and development by the pharmaceutical industry. The market's expansion is further fueled by the rising prevalence of various diseases, which encourages biopharmaceutical companies to invest in clinical trials for new and rare disease segments. The COVID-19 pandemic, while initially disruptive, ultimately led to a surge in clinical trials focused on COVID-19 treatments, benefiting the market. The United States, in particular, leads the region with a high volume of clinical studies, supported by a robust healthcare infrastructure, increased pharmaceutical budgets, and a strong focus on new therapies. This dominance is expected to continue, with Phase III trials playing a crucial role in determining treatment efficacy and safety, thereby facilitating the commercialization of new therapies.
The competitive landscape of the North America clinical trials market is characterized by the presence of major pharmaceutical companies and strategic partnerships with contract research organizations (CROs). These collaborations are anticipated to significantly impact market growth, as companies like Eli Lilly, Novartis, Pfizer, and Hoffmann-La Roche lead numerous clinical studies in the United States. The market is fragmented, with key players making substantial investments in R&D to capitalize on growth opportunities. The ongoing demand for novel therapeutics, particularly for prominent diseases such as cancer, cardiac, and respiratory disorders, is driving the increase in clinical trials. As a result, the North America clinical trials market is expected to experience robust growth over the forecast period, with the United States holding a significant market share.
North America Clinical Trials Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Demand for Clinical Trials
-
1.2.2 High R&D Expenditure of the Pharmaceutical Industry
-
1.2.3 Rising Prevalence of Diseases
-
-
1.3 Market Restraints
-
1.3.1 Lack of Skilled Workforce for Clinical Research
-
1.3.2 Stringent Regulations
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Phase
-
2.1.1 Phase I
-
2.1.2 Phase II
-
2.1.3 Phase III
-
2.1.4 Phase IV
-
-
2.2 By Design
-
2.2.1 Treatment Studies
-
2.2.1.1 Randomized Control Trial
-
2.2.1.1.1 Double Blind Trial Randomized Trial
-
2.2.1.1.2 Single Blind Trial Randomized Trial
-
2.2.1.1.3 Non-blind Randomized Trial
-
-
2.2.1.2 Adaptive Clinical Trial
-
2.2.1.3 Non-randomized Control Trial
-
-
2.2.2 Observational Studies
-
2.2.2.1 Cohort Study
-
2.2.2.2 Case Control Study
-
2.2.2.3 Cross Sectional Study
-
2.2.2.4 Ecological Study
-
-
-
2.3 Geography
-
2.3.1 United States
-
2.3.2 Canada
-
2.3.3 Mexico
-
-
North America Clinical Trials Market Size FAQs
What is the current North America Clinical Trials Market size?
The North America Clinical Trials Market is projected to register a CAGR of 8.10% during the forecast period (2024-2029)
Who are the key players in North America Clinical Trials Market?
Novo Nordisk AS, ICON Plc, Eli Lilly and Company, IQVIA and Clinipace are the major companies operating in the North America Clinical Trials Market.
